Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors it now has potentially enough clinical-grade supply of its DMT psychedelic compound to complete its planned Phase 1 and Phase 2 clinical trials for stroke and appointed two medical experts in the field as consultants.
The drug-repurposing company is advancing AP-188 (N,N-Dimethyltryptamine, or DMT) as a potential treatment for stroke and the manufacturing was completed at Canadian manufacturer Dalton Pharma Services.
Meanwhile, UK-based Dr. Anthony Rudd and Dr. Robert Simister have been named as consultants for its DMT stroke clinical research program, of which the Phase 1 part in London is earmarked to begin in January 2022.
Their main responsibility will be to help guide the Phase 2 acute stroke and post-stroke therapy clinical trials in the UK planned for the latter part of 2022 after the Phase 1 trial has been completed, said Algernon.
READ: Algernon Pharmaceuticals projects full enrollment for its Phase 2 pulmonary fibrosis and chronic cough trial using Ifenprodil
CEO Christopher J. Moreau added: "Completing production of a cGMP supply of DMT is a major milestone for the company’s clinical stroke research program and it ensures that we will have a supply of the drug for our planned Phase 1 and 2 clinical trials.
"We are also very pleased to have Dr. Rudd and Dr. Simister join as medical consultants as we now begin the process of planning our Phase 2 studies for both acute stroke and for therapy post stroke."
Educated at Cambridge and King’s College London, Dr. Rudd is an emeritus professor of stroke medicine at Kings College London and recently retired as a consultant stroke physician at Guy’s and St Thomas’ Hospital.
For more than 20 years he chaired the intercollegiate stroke working party at the Royal College of Physicians which was responsible for developing the national clinical guidelines for stroke and running the national sentinel stroke audit program.
Dr. Simister is a consultant neurologist and stroke physician as well as an honorary senior lecturer at University College London, where he also serves as the clinical lead for the comprehensive stroke service and the clinical director of stroke medicine and acute neurology.
Contact the writer at giles@proactiveinvestors.com